Drug Profile
Research programme: bladder cancer therapeutics - Aurora Oncology
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator University of Colorado at Anschutz Medical Campus
- Developer Aurora Oncology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Bladder-cancer in USA (Parenteral)